A recent ACG “Negative Issue” had some terrific articles –thanks to Ben Gold for sharing his issue.
Here are a few of the studies:
- Buspirone had similar efficacy as placebo in a randomized clinical trial for childhood functional abdominal pain, (n=117) Full text: Comparison of the Efficacy of Buspirone and Placebo in Childhood Functional Abdominal Pain Key finding: Treatment response rates for buspirone and placebo were 58.3% and 59.6% at week 4 (P = 0.902) and 68.1% and 71.1% at week 12 (P = 0.753), respectively.
- IBS does not increase mortality in a nationwide cohort study (>300,000 in study) Full text: Mortality Risk in Irritable Bowel Syndrome Key finding: After adjustment for confounders, IBS was not linked to mortality (HR = 0.96; 95% CI = 0.92–1.00) …and patients with IBS not undergoing a colorectal biopsy were at no increased risk of death (HR = 1.02; 95% CI = 0.99–1.06).
- Mongerson was not effective for active Crohn’s disease in a large phase 3 study, n=701 Full text: Mongersen (GED-0301) for Active Crohn’s Disease Key finding: The primary endpoint, clinical remission achievement (CD Activity Index score <150) at week 12, was attained in 22.8% of patients on GED-0301 vs 25% on placebo (P = 0.6210). At study termination, proportions of patients achieving clinical remission at week 52 were similar among individual GED-0301 groups and placebo.
- Treatment of H pylori did not increase the risk of C difficile infection (retrospective study) Full text: Treatment of Helicobacter pylori & Clostridium difficile Key finding: Of these 38,535 patients with H pylori based on endoscopic pathology, urea breath testing, or stool antigen, 284 (0.74%) had subsequent CDI. Those who developed CDI were less likely to have received treatment for HP within the VHA (66.2% vs 74.8%, P < 0.001)
- Percutaneous liver biospy was not safer when done by experienced clinician compared to a fellow, n=212 biopsies Full text: Major Complications of Pediatric Percutaneous Liver Biopsy Do Not Differ Among Physicians With Different Degrees of Training Key finding: No significant differences were found between groups (fellows vs staff) regarding number of punctures (median of 1.7 for both), nonrepresentative biopsies (4.2% vs 2.6%), and hemoglobin drop (median of 0.7 vs 0.5 g/L). Interestingly, in the discussion, the authors assert: “previous studies do not support the conclusion that ultrasound-guided biopsies are superior in terms of safety or adequacy when compared with the use of ultrasound to mark the puncture” (this is based on a study referenced from 2007: J Gastroenterol Hepatol 2007;22(9):1490–3.) However, given that severe complications from liver biopsy are infrequent, this current study may be underpowered to detect a small difference between experienced clinicians and fellows.
Related blog posts:
- Does buspirone help functional dyspepsia?
- Brave New World: Psychotropic Medications and Pediatric Functional GI Disorders
- A 6-Year Study of Amitriptyline, Escitalopram, and Functional Dyspepsia
- Advice on Abdominal Pain for Everyone Who Cares for Children | gutsandgrowth
- Dreaded Nausea (2017) | gutsandgrowth
- Mongerson -Phase 2 Study Data
- An Oral Oligonucleotide in the Crohn’s Treatment Pipeline & Smart Patients
- Optimism for New Treatment in Inflammatory Bowel Disease: AJM300 | gutsandgrowth
- Outpatient liver biopsy
- Liver biopsy -risks and benefits
- Liver biopsy risk in children | gutsandgrowth
It’s come to this: Link: YouTube: Dirty Dancing Remake -Safest with a Lamp (this link is for Bernsie). 4 minute video.